Amneal Gains Approval for Erythromycin Tablets USP

[End Subhead]
[Start Distributor]
PR Newswire 14-Mar-2018 8:00 AM
[End Distributor]
BRIDGEWATER, N.J., March 14, 2018 /PRNewswire/ --Amneal Pharmaceuticals has received FDA approval for Erythromycin Tablets USP, 250 mg and 500 mg strengths. The Amneal product is a therapeutic equivalent for the reference listed drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals and is the only other immediate release oral tablet available.

"Amneal is committed to increasing access to affordable medications," said Amneal EVP-Commercial Operations Andy Boyer. "Erythromycin tablets are a great example of a product with limited availability where we can now provide patients and pharmacists with options."
Amneal's erythromycin tablets are sold in 100-count bottles and are now available to wholesalers, distributors and direct to the trade.
Annual U.S. sales of erythromycintablets were $84 million, according to January 2018 IQVIA market data.
About Amneal
Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and the fastest growing generics pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 5,000 employees in North America, Asia and Europe, working together to bring high quality affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas.
Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) announced on October 17, 2017 that they have entered into a definitive business combination agreement with the resulting combined company expected to create the 5th largest generics business (by gross revenue) in the United States. The transaction is expected to close in the first half of 2018.
For more information, visit amneal.com.
All trademarks listed in this release are property of their respective owners. Product photo is available upon request.
[Start Table]
CONTACTS:

Sales
Andy Boyer
Executive Vice President, Commercial Operations
908.409.6891 Business Development
andy.boyer@amneal.com Apurva Saraf
Vice President, Global Strategy & Corporate Development
Media 631.742.7674
Cheryl Lechok apurvas@amneal.com
Media Relations
203.613.1506
mediarelations@amneal.com

[End Table]
View original content with multimedia:http://www.prnewswire.com/news-releases/amneal-gains-approval-for-erythromycin-tablets-usp-300613712.html
SOURCE Amneal Pharmaceuticals LLC